Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma

C-Jun drives melanoma progression in PTEN wild type melanoma cells

(2019) Melanie Kappelmann-Fenzl et al.   Cell Death & Disease

AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma

(2018) Qiang Zuo et al.   ONCOGENE

In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms

(2018) Jessica L.F. Teh et al.   Cancer Discovery

A Preexisting Rare PIK3CA E545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling

(2018) Gabriele Romano et al.   Cancer Discovery

MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition

(2017) Teresa Amaral et al.   EUROPEAN JOURNAL OF CANCER

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas

(2017) Hezhe Lu et al.   NATURE

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

(2017) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma

(2017) Clemens Krepler et al.   Cell Reports

Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?

(2016) Sarah J. Welsh et al.   EUROPEAN JOURNAL OF CANCER

Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors

(2016) Patricia Mucci LoRusso   JOURNAL OF CLINICAL ONCOLOGY

mTORC1 and mTORC2 in cancer and the tumor microenvironment

(2016) L C Kim et al.   ONCOGENE

BEZ235: When Promising Science Meets Clinical Reality

(2016) G. Pongas et al.   ONCOLOGIST

A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma

(2016) Maria I. Carlo et al.   ONCOLOGIST

BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition

(2015) Zhan Yao et al.   CANCER CELL

Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction

(2015) Gatien Moriceau et al.   CANCER CELL

Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

(2015) C. Krepler et al.   CLINICAL CANCER RESEARCH

Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma

(2015) Lawrence N. Kwong et al.   JOURNAL OF CLINICAL INVESTIGATION

PTEN regulates IGF-1R-mediated therapy resistance in melanoma

(2015) Jun Wang et al.   Pigment Cell & Melanoma Research

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma

(2015) Siwen Hu-Lieskovan et al.   Science Translational Medicine

Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade

(2015) Ilaria Penna et al.   Oncotarget

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

(2015) Melanie Sweetlove et al.   Frontiers in Oncology

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers

(2015) Ryan B. Corcoran et al.   Oncotarget

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1  and Oxidative Phosphorylation in Melanoma

(2014) Y. N. V. Gopal et al.   CANCER RESEARCH

BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

(2014) H. Rizos et al.   CLINICAL CANCER RESEARCH

Systemic treatment for BRAF-mutant melanoma: where do we go next?

(2014) Alexander M Menzies et al.   LANCET ONCOLOGY

BRAF V600E Cooperates with PI3K Signaling, Independent of AKT, to Regulate Melanoma Cell Proliferation

(2014) Jillian M. Silva et al.   MOLECULAR CANCER RESEARCH

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

(2014) Chong Sun et al.   NATURE

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies

(2014) Lise Boussemart et al.   NATURE

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

(2014) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

(2014) Georgina V. Long et al.   Nature Communications

A pan-cancer proteomic perspective on The Cancer Genome Atlas

(2014) Rehan Akbani et al.   Nature Communications

Targeting PI3K/Akt/mTOR Signaling in Cancer

(2014) Camillo Porta et al.   Frontiers in Oncology

Coordinate Autophagy and mTOR Pathway Inhibition Enhances Cell Death in Melanoma

(2013) Xiaoqi Xie et al.   PLoS One

TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma

(2013) R. B. Corcoran et al.   Science Translational Medicine

A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition

(2013) H. Shi et al.   Cancer Discovery

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

(2013) H. Shi et al.   Cancer Discovery

MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

(2013) N. Wagle et al.   Cancer Discovery

The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

(2013) E. M. Van Allen et al.   Cancer Discovery

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma

(2013) Jessie Villanueva et al.   Cell Reports

Roles of the mammalian target of rapamycin, mTOR, in controlling ribosome biogenesis and protein synthesis: Figure 1

(2012) Valentina Iadevaia et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

The mTOR Signalling Pathway in Human Cancer

(2012) Helena Pópulo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

(2012) J. G. Greger et al.   MOLECULAR CANCER THERAPEUTICS

Combinatorial Treatments That Overcome PDGFR -Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition

(2011) H. Shi et al.   CANCER RESEARCH

PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression

(2011) K. H. T. Paraiso et al.   CANCER RESEARCH

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

(2011) Nikhil Wagle et al.   JOURNAL OF CLINICAL ONCOLOGY

Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition

(2011) W. Deng et al.   Pigment Cell & Melanoma Research

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

(2011) Mohammad Atefi et al.   PLoS One

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

(2011) Michelle C. Mendoza et al.   TRENDS IN BIOCHEMICAL SCIENCES

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells

(2010) Y. N. V. Gopal et al.   CANCER RESEARCH

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma

(2010) V. E. Kwitkowski et al.   ONCOLOGIST

BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation

(2010) R. B. Corcoran et al.   Science Signaling

An Emerging Role of mTOR in Lipid Biosynthesis

(2009) Mathieu Laplante et al.   CURRENT BIOLOGY

mTOR and cancer: many loops in one pathway

(2009) Alejo Efeyan et al.   CURRENT OPINION IN CELL BIOLOGY

mTOR signaling at a glance

(2009) M. Laplante et al.   JOURNAL OF CELL SCIENCE

Targeting the mTOR Signaling Network for Cancer Therapy

(2009) Funda Meric-Bernstam et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular mechanisms of mTOR-mediated translational control

(2009) Xiaoju Max Ma et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors

(2009) T John et al.   ONCOGENE

MEK1 mutations confer resistance to MEK and B-RAF inhibition

(2009) C. M. Emery et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

(2008) V. Serra et al.   CANCER RESEARCH